RecruitingPhase 3NCT05703672

Switching to E-cigarettes in Smokers Not Interested in Quitting

4th Generation E-cigarettes: Reducing Harm and Quitting Combustible Cigarettes in Dual Users


Sponsor

University of Kansas Medical Center

Enrollment

500 participants

Start Date

Jul 17, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

The objectives of this application are to 1) compare short- and long-term harm reduction and abuse liability potential of a nicotine salt pod-based electronic cigarettes (EC) in adult (AA) exclusive EC, dual cig-EC, and exclusive cig users, 2) characterize factors that predict who switches fully, partially, or not at all, and 3) examine if harm reduction can be further enhanced by treating dual users with varenicline (VAR) to eliminate cigarette smoking.


Eligibility

Min Age: 21 Years

Inclusion Criteria7

  • ≥ 21 years of age
  • Smoke >5 cigarettes per day
  • Smoked cigarettes for > 6 months
  • Verified smoker (CO > 5 ppm)
  • Functioning telephone
  • Interested in switching to EC
  • Willing to take varenicline and complete all study visits

Exclusion Criteria10

  • Interested in quitting smoking
  • Use of smoking cessation pharmacotherapy in the month prior to enrollment
  • Use of other tobacco products in past 30 days (i.e., cigarillos, cigars, hookah, smokeless tobacco, pipes)
  • EC use on > 4 of the past 30 days
  • Uncontrolled hypertension: BP > 180 (systolic) or > 105 (diastolic)
  • Heart-related event in the past 30 days
  • Medical contraindications to VAR: unstable cardiac condition (e.g., unstable angina or AMI) cardiac event, or stroke in the past 4 weeks; renal impairment; history of clinically significant allergic reactions; history of epilepsy or seizure disorder; hospitalized for psychiatric issue in past 30 days; active suicidal ideation
  • Pregnant, contemplating getting pregnant, or breastfeeding
  • Plans to move from Kansas City metro area during the treatment and follow-up phase
  • Another household member enrolled in the study

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGVarenicline Tartrate

0.5 mg once daily for days 1-3, 0.5mg twice daily for days 4-7 and 1.0 mg twice daily from day 8 through week 12.

DRUGPlacebo

One pill (white) once daily for days 1-3, one pill (white) twice daily for days 4-7 and one pill (blue) twice daily from day 8 through week 12.

OTHERElectronic cigarette

Nicotine salt pod based e-cigarette in 5% nicotine


Locations(2)

Swope Health Central

Kansas City, Missouri, United States

University of Kansas Medical Center

Kansas City, Missouri, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05703672


Related Trials